BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
PFA re-energizes afib market
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Saturday, September 7, 2024
See today's BioWorld MedTech
Home
» A royalty pain: Zimmer liable for payments despite patent expiry
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
A royalty pain: Zimmer liable for payments despite patent expiry
July 22, 2024
By
Mark McCarty
No Comments
Royalties for licensed patents ordinarily need not be paid after the underlying patent has expired, but the case of
Zimmer Biomet Holdings Inc. v. Insall
would seem to throw out a cautionary flag regarding such agreements.
BioWorld MedTech
Regulatory
Orthopedics
U.S.